A test of financial incentives to improve warfarin adherence

Kevin G Volpp, George Loewenstein, Andrea B Troxel, Jalpa Doshi, Maureen Price, Mitchell Laskin, Stephen E Kimmel, Kevin G Volpp, George Loewenstein, Andrea B Troxel, Jalpa Doshi, Maureen Price, Mitchell Laskin, Stephen E Kimmel

Abstract

Background: Sub-optimal adherence to warfarin places millions of patients at risk for stroke and bleeding complications each year. Novel methods are needed to improve adherence for warfarin. We conducted two pilot studies to determine whether a lottery-based daily financial incentive is feasible and improves warfarin adherence and anticoagulation control.

Methods: Volunteers from the University of Pennsylvania Anticoagulation Management Center who had taken warfarin for at least 3 months participated in either a pilot study with a lottery with a daily expected value of $5 (N = 10) or a daily expected value of $3 (N = 10). All subjects received use of an Informedix Med-eMonitor System with a daily reminder feature. If subjects opened up their pill compartments appropriately, they were entered into a daily lottery with a 1 in 5 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 1) or a 1 in 10 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 2). The primary study outcome was proportion of incorrect warfarin doses. The secondary outcome was proportion of INR measurements not within therapeutic range. Within-subject pre-post comparisons were done of INR measurements with comparisons with either historic means or within-subject comparisons of incorrect warfarin doses.

Results: In the first pilot, the percent of out-of-range INRs decreased from 35.0% to 12.2% during the intervention, before increasing to 42% post-intervention. The mean proportion of incorrect pills taken during the intervention was 2.3% incorrect pills, compared with a historic mean of 22% incorrect pill taking in this clinic population. Among the five subjects who also had MEMS cap adherence data from warfarin use in our prior study, mean incorrect pill taking decreased from 26% pre-pilot to 2.8% in the pilot. In the second pilot, the time out of INR range decreased from 65.0% to 40.4%, with the proportion of mean incorrect pill taking dropping to 1.6%.

Conclusion: A daily lottery-based financial incentive demonstrated the potential for significant improvements in missed doses of warfarin and time out of INR range. Further testing should be done of this approach to determine its effectiveness and potential application to both warfarin and other chronic medications.

Figures

Figure 1
Figure 1
Adherence under lotteries compared to historic controls.
Figure 2
Figure 2
Differences in time out-of-range INRs while in lottery compared to pre-enrollment.

References

    1. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–1647. doi: 10.1001/archinte.158.15.1641.
    1. Madden KP, Karanjia PN, Adams HP, Jr, Clarke WR. Accuracy of initial stroke subtype diagnosis in the TOAST study. Trial of ORG 10172 in Acute Stroke Treatment. Neurology. 1995;45:1975–1979.
    1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581–1587. doi: 10.1056/NEJM199512143332401.
    1. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998;279:1265–1272. doi: 10.1001/jama.279.16.1265.
    1. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736–743.
    1. Singer DE. Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiol. 1993;3:563–567.
    1. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259–270. doi: 10.1016/S0033-0620(75)80017-X.
    1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175–179. doi: 10.1016/S0140-6736(89)91200-2.
    1. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255–1262.
    1. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513–1521. doi: 10.1001/archinte.158.14.1513.
    1. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579S–589S. doi: 10.1378/chest.114.5_Supplement.579S.
    1. Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998;114:561S–578S. doi: 10.1378/chest.114.5_Supplement.561S.
    1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. doi: 10.1001/archinte.154.13.1449.
    1. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423–428. doi: 10.1016/S0140-6736(96)01109-9.
    1. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996;124:970–979.
    1. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511–520.
    1. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R. The Influence of Patient Adherence on Anticoagulation Control with Warfarin: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007
    1. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97:1231–1233.
    1. Cheng TO. Underuse of warfarin in atrial fibrillation. Arch Intern Med. 1997;157:1505. doi: 10.1001/archinte.157.13.1505b.
    1. Coughlin CC, Garrett TA, Hernandez-Murillo R. The geography, economics, and politics of lottery adoption. Federal Reserve Bank of St Louis Review. 2006;88:165–180.
    1. Ainslie G. Specious reward: A behavioral theory of impulsiveness and impulse control. Psychol Bull. 1975;82:463–496. doi: 10.1037/h0076860.
    1. Loewenstein G, Prelec D. Anomalies in intertemporal choice: Evidence and an interpretation. Quarterly Journal of Economics. 1992;107:573–597. doi: 10.2307/2118482.
    1. Kahneman D, Tversky A. Prospect theory: An analysis of decision under risk. Econometrica. 1979;47:263–291. doi: 10.2307/1914185.
    1. Connolly T, Butler DU. Regret in Economic and Psychological Theories of Choice. Journal of Behavioral Decision Making. 2006;19:148–158. doi: 10.1002/bdm.510.
    1. Shaw J. Is it acceptable for people to be paid to adhere to medication? No. Bmj. 2007;335:233. doi: 10.1136/.
    1. Burns T. Is it acceptable for people to be paid to adhere to medication? Yes. Bmj. 2007;335:232. doi: 10.1136/.
    1. Bains N, Pickett W, Hoey J. The use and impact of incentives in population-based smoking cessation programs: a review. Am J Health Promot. 1998;12:307–320.
    1. Kane RL, Johnson PE, Town RJ, Butler M. A structured review of the effect of economic incentives on consumers' preventive behavior. Am J Prev Med. 2004;27:327–352. doi: 10.1016/j.amepre.2004.07.002.
    1. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA. 2008;300:2631–2637. doi: 10.1001/jama.2008.804.
    1. Thaler RH. Some empirical evidence on time inconsistency. Review of Economic Studies. 1981;23:165–180.
    1. Kirby K. Bidding on the future: evidence against normative discounting of delayed rewards. Journal of Experimental Psychology: General. 1997;126:54–70. doi: 10.1037/0096-3445.126.1.54.
    1. Camerer C, Ho T-H. Experience-Weighted Attraction Learning in Normal Form Games. Econometrica. 1999;67:837–874. doi: 10.1111/1468-0262.00054.
    1. Loewenstein G, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychological Bulletin. 2001;127:267–286. doi: 10.1037/0033-2909.127.2.267.
    1. Chapman GB, Coups EJ. Emotions and Preventive Health Behavior: Worry, Regret, and Influenza Vaccination. Health Psychol. 2006;25:82–90. doi: 10.1037/0278-6133.25.1.82.
    1. Prelec D. The Probability Weighting Function. Econometrica. 1998;66:497–527. doi: 10.2307/2998573.
    1. Loewenstein G, Brennan T, Volpp KG. Asymmetric paternalism to improve health behaviors. JAMA. 2007;298:2415–2417. doi: 10.1001/jama.298.20.2415.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する